Skip to main content
TipRanks
Go Ultimate75% OFF

Isofol Medical AB (5IU) Stock Price & Analysis

1 Followers

5IU Stock Chart & Stats

€0.08€0.00(5.26%)
At close: 5:30 PM GMT+1
€0.07€0.08€0.09€0.1Sep 18Nov 5
Day’s Range
EUR 0.08 - EUR 0.08
52-Week Range
EUR 0.04 - EUR 0.13
Previous Close
EUR 0.08
Volume
N/A
Average Volume (3M)
2,000
Market Cap
EUR 30.52M
Enterprise Value
EUR 145.49M
Total Cash (Recent Filing)
EUR 114.83M
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
0.21
Next Earnings
Feb 12, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Focused Oncology Pipeline

A focused oncology candidate gives Isofol a defined development strategy rather than a broad, unfocused research portfolio. If clinical and regulatory objectives are achieved, arfolitixorin could support a scalable product opportunity within established chemotherapy treatment pathways.

Very Low Financial Leverage

Zero recent debt reduces fixed financing obligations and limits exposure to refinancing or interest-cost pressure. This gives management greater flexibility to allocate available resources toward clinical development and preserves balance-sheet resilience while the company remains pre-commercial.

Potential Partnering Pathway

The stated commercialization model provides more than one route to future monetization: Isofol could commercialize directly or pursue licensing and partnerships. Although conditional on development success, this creates strategic flexibility for funding, distribution, and revenue generation.

Bears Say

No Meaningful Commercial Revenue

The absence of meaningful revenue confirms that Isofol has not yet established a commercial earnings base. Until a product is approved and adopted, operating performance will remain tied to development progress rather than recurring customer demand or product sales.

Sustained Operating Cash Burn

Material operating cash consumption means Isofol cannot currently fund its activities from internally generated cash. Continued development therefore depends on existing reserves or additional financing, creating ongoing capital-raising pressure and potential constraints on operating plans.

Persistent Losses And Equity Erosion

Deep and recurring losses reduce the capital base and weaken earnings quality while the company remains pre-commercial. Continued negative profitability can limit financial flexibility, increase dependence on shareholders, and make progress toward self-sustaining operations more difficult.

Isofol Medical AB News

5IU FAQ

What was Isofol Medical AB’s price range in the past 12 months?
Isofol Medical AB lowest stock price was €0.04 and its highest was €0.13 in the past 12 months.
What is Isofol Medical AB’s market cap?
Isofol Medical AB’s market cap is €30.52M.
When is Isofol Medical AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Isofol Medical AB’s earnings last quarter?
Isofol Medical AB released its earnings results on Nov 12, 2026. The company reported -€0.003 earnings per share for the quarter.
Is Isofol Medical AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Isofol Medical AB pay dividends?
Isofol Medical AB does not currently pay dividends.
What is Isofol Medical AB’s EPS estimate?
Isofol Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Isofol Medical AB have?
Isofol Medical AB has 320,491,640 shares outstanding.
What happened to Isofol Medical AB’s price movement after its last earnings report?
Isofol Medical AB reported an EPS of -€0.003 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Isofol Medical AB?
Currently, no hedge funds are holding shares in DE:5IU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology